Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biological therapies: a long way on from Jenner.

Literature DB >> 23879267

Biological therapies: a long way on from Jenner.

Albert Ferro, Malcolm Boyce.

Abstract

Mesh：

Year: 2013 PMID： 23879267 PMCID： PMC3731591 DOI： 10.1111/bcp.12202

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

13 in total

Review 1. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.

Authors: Stanley T Crooke; Richard S Geary
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Review 2. A regulatory perspective of clinical trial applications for biological products with particular emphasis on Advanced Therapy Medicinal Products (ATMPs).

Authors: David R Jones; James W McBlane; Graham McNaughton; Nishanthan Rajakumaraswamy; Kirsty Wydenbach
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Review 3. A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Authors: Dominic Smethurst
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Review 4. How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes.

Authors: Marianne Böni-Schnetzler; Marc Y Donath
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Review 5. Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing.

Authors: John S Oxford
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Review 6. Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Authors: Chern Siang Lee; Mark Cragg; Martin Glennie; Peter Johnson
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Review 7. A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus.

Authors: John Ferbas; Shelley S Belouski; Michelle Horner; Arunan Kaliyaperumal; Li Chen; Malcolm Boyce; C Bernie Colaço; Neil McHugh; Vanessa Quick; Richard J Nicholl; Gerald Siu; James Chung
Journal: Br J Clin Pharmacol Date: 2013-08 Impact factor: 4.335

Biological therapies: a long way on from Jenner.

Review 1. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.

Review 2. A regulatory perspective of clinical trial applications for biological products with particular emphasis on Advanced Therapy Medicinal Products (ATMPs).

Review 3. A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Review 4. How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes.

Review 5. Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing.

Review 6. Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Review 7. A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus.

Review 8. Drug-conjugated antibodies for the treatment of cancer.

Review 9. Stratified approaches to the treatment of asthma.

10. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

1. Sensitive, homogeneous, and label-free protein-probe assay for antibody aggregation and thermal stability studies.